InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.83
(
-0.36%
)
Bitcoin
64,213.06
(
0.33%
)
Post# of 110
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

GGraessle

Send PM Follow Ignore
Followers 20
Posts 2942
Boards Moderated 1
Alias Born 04/27/2000

GGraessle

Member Level

Re: None

Monday, 02/24/2003 9:37:34 AM

Monday, February 24, 2003 9:37:34 AM

Post# of 110
IBCI Answers Questions And Clarifies Last Two Press Releases
Monday February 3, 9:01 am ET


ATLANTA, Feb. 3 /PRNewswire-FirstCall/ -- International BioChemical Industries, Inc. (OTC Bulletin Board: IBCL - News) answers questions and clarifies last two press releases.

IBCI was contacted on Tuesday, January 28, 2003, by a Weapons of Mass Destruction Coordinator for the FBI, who is also a member of the Atlanta Joint Task Force on Terrorism. On Wednesday afternoon, January 29, 2003, IBCI again talked to the FBI Agent to establish a meeting time on Monday morning, February 3, 2003, between 9:30 and 10:00 am. The meeting is planned to last approximately two hours, with discussions to be held at the IBCI offices located in Norcross, Ga. The items to be discussed include business operations of IBCI, company efforts over the last 14 months relating to products, and the stability and security of the business.

IBCI is prepared to discuss everything requested by the agent, including manufacturing capabilities, good laboratory practices and protocols, security of the facility and security of internal data files on Anthrax, including test locations and employee confidentiality, all of which relate to the business operations.

IBCI Management wants to remind investors that the firm currently does not have a contract with the Federal Government, nor has one been presented. The company is anxious to find out today, but does not know at this time, the exact level of interest in the company's products. Management strongly encourages all investors to review the public filings prior to making any investment decisions.

About International BioChemical Industries:

International BioChemical Industries, Inc. is a Norcross, Georgia-based emerging growth company focused in biotechnology and antimicrobial products. Its core business is committed to the discovery, development, marketing and sale of surface-modifying antimicrobial and biostatic products. The company's antimicrobial technology is an alternative to conventional sanitizers, disinfectants, bleaches, biocides or preservatives primarily because it kills bacteria on contact and can remain active for extended time periods. To date IBCI has received four U.S. patents and eight EPA registrations, including the first U.S. germ killer and disinfectant against Salmonella cholerasuis, Staphylococcus aureus and other microorganisms. The company has developed several alliances in different industries, such as healthcare, textiles and storm water.

Further information on IBCI and its line of products can be found by visiting the firm's web site at http://www.bioshield.com , or by calling 1-770-925-3653, Tim Moses.

Safe Harbor/Forward-looking Statements:

Statements in this news release that are not historical are forward- looking statements. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in any forward-looking statements, all of which are difficult to predict and many of which are beyond the control of the company, including areas such as: developing technologies; dependence on collaborative partners; the inherent complexity and uncertainty regarding the development of products; early-stage development of IBCI; the result of research and development efforts; future capital needs; uncertainty of additional funding; government regulations; and other factors which are detailed in the company's periodic reports and registration statements filed with the Securities and Exchange Commission. IBCI does not undertake to revise or update any forward- looking statement to reflect events or circumstances that may arise after the date hereof. BioShield is a trademark of IBCI.





The best weapon against "fear" is "facts"!!

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up